We are live on
!
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter
Est. Return
-9.37%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$840M
AUM Growth
-$29.6M
(-3.4%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
6.59%
Top 10 Holdings %
Top 10 Hldgs %
70.69%
Holding
42
New
7
Increased
11
Reduced
10
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$17.7M |
| 2 |
Medtronic
MDT
|
+$14.7M |
| 3 |
Amgen
AMGN
|
+$11.8M |
| 4 |
CORI
Corium International, Inc.
CORI
|
+$7.25M |
| 5 |
IMPR
IMPRIVATA, INC COM
IMPR
|
+$7.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$17.9M |
| 2 |
MiMedx Group
MDXG
|
+$15.1M |
| 3 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$11.6M |
| 4 |
Bruker
BRKR
|
+$10.2M |
| 5 |
ICU Medical
ICUI
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.91% |
| 2 | Technology | 3.01% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $5.06M | 0.6% |
375,000
-129,668
| -26% | -$1.76M |
|
27
Cerus
CERS
$627M
| $4.09M | 0.49% |
900,000
+34,830
| +4% | +$180K |
|
28
Lantheus
LNTH
$7B
| $2.65M | 0.31% |
615,000
-1,155,918
| -65% | -$7.79M |
|
|
STRM
29
DELISTED
Streamline Health Solutions
STRM
| $2.61M | 0.31% |
75,867
| – | – |
|
30
Heron Therapeutics
HRTX
$89.1M
| $1.83M | 0.22% |
+75,000
| New | +$2.5M |
|
|
NUVA
31
DELISTED
NuVasive, Inc.
NUVA
| $1.21M | 0.14% |
+25,000
| New | +$1.29M |
|
32
Globus Medical
GMED
$10.5B
| $930K | 0.11% |
+45,000
| New | +$1.14M |
|
|
33
Bruker
BRKR
$8.86B
| – | – |
-500,709
| Closed | -$10.2M |
|
|
34
ICU Medical
ICUI
$3.94B
| – | – |
-105,776
| Closed | -$10.1M |
|
35
Inogen
INGN
$178M
| – | – |
-75,000
| Closed | -$3.35M |
|
|
36
MiMedx Group
MDXG
$640M
| – | – |
-1,300,000
| Closed | -$15.1M |
|
37
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
| – | – |
-400,000
| Closed | -$82.3M |
|
38
Supernus Pharmaceuticals
SUPN
$2.79B
| – | – |
-150,000
| Closed | -$2.55M |
|
39
Bio-Techne
TECH
$11.2B
| – | – |
-323,116
| Closed | -$7.95M |
|
|
HMSY
40
DELISTED
HMS Holdings Corp.
HMSY
| – | – |
-329,246
| Closed | -$5.65M |
|
|
CTRX
41
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| – | – |
-189,802
| Closed | -$11.6M |
|
Similar funds
RI
CWA
GHF
F
TRV
BMCMI
GACM
AH
Tamarack Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Tamarack Capital Management held 42 positions worth $840M, down 3.4% from $870M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Tamarack Capital Management deployed $55.4M of net new capital in Q3 2015, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Amgen: 75,000 shares worth $10.4M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 57% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Becton Dickinson, an estimated $17.9M trimmed.
- Tamarack Capital Management's largest Q3 2015 buy was Amgen: 75,000 shares worth $10.4M.
- Tamarack Capital Management added most to Patterson Companies, Inc. in Q3 2015, an estimated $17.7M increase.
- Tamarack Capital Management's biggest Q3 2015 reduction was Becton Dickinson, cutting an estimated $17.9M.
- Tamarack Capital Management fully exited MiMedx Group in Q3 2015, selling an estimated $15.1M.
- Tamarack Capital Management's ten largest holdings make up 71% of its $840M portfolio in Q3 2015.
- Tamarack Capital Management opened 7 new positions and closed 10 in Q3 2015.
- Tamarack Capital Management's portfolio value fell 3.4% quarter-over-quarter to $840M.
Based on Tamarack Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.